Interesting and fits into JJ rationale with these recent statements;
"The rationale for launching Exosome Sciences was driven by the belief we could transform an unvalued asset into a substantially valued asset that would benefit our shareholders."
And
"As a therapeutic organization, our primary focus is the clinical advancement and future commercialization of the Aethlon Hemopurifer® in the United States and abroad. With this mind, our objective with ESI is to transform a currently dormant and unvalued diagnostic asset into a stand-alone organization that contributes measurable asset value to Aethlon shareholders, yet does not dilute our team's focus away from advancing first-in-class therapeutic devices. It also became clear that the launch of ESI might allow us to leverage recent valuations that have been awarded to molecular diagnostic organizations with novel technology strategies."
Market Data 
Markets 
AI
